News

Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent®. Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent...

Zenith Capital Corp. announced  that Zenith Epigenetics Ltd. , a wholly-owned subsidiary of Zenith Capital, has entered into a licensing agreement with Newsoara BioPharma Co., Ltd. for the Company’s lead compound, ZEN-3694, in China, Hong Kong, Taiwan, and Macau...

Aucta Pharmaceuticals, Inc. ,a technology based company focusing on the development and commercialization of Branded Specialty Products, announced that the Company has entered into an exclusive license agreement with Jiangsu Wanbang Biopharmaceuticals Group Co., Ltd., a subsidiary of Shanghai...

Sempre Health, the leading solution for behavior-based healthcare pricing, announced a partnership with Blue Cross Blue Shield of Arizona (BCBSAZ) that features a new way for BCBSAZ members to save on medications. Starting this month, many BCBSAZ members will...

Daiichi Sankyo Company, Limited announced that the U.S. FDA approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is...

Amicus Therapeutics announced that the Agency of Medicines, Food and Medical Devices (ANMAT) in Argentina has granted approval for the first-in-class, oral small molecule pharmacological chaperone Galafold® (migalastat), as a monotherapy for the treatment of people aged 16 years...

Amicus Therapeutics  announced positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital. AWRI is conducting the ongoing Phase 1/2 clinical study of a single one-time...